期刊文献+

包载雷帕霉素的聚乳酸-聚乙醇酸纳米粒子对小型猪冠状动脉损伤后平滑肌细胞增殖的影响及机制

Efficacy and mechanism of local delivery of rapamycin and rapamycin-loaded poly (lactic-coglycolic) acid nanoparticles on coronary restenosis of injury-stenosis model of minipigs
原文传递
导出
摘要 目的研究局部血管内灌注包载雷帕霉素(RPM)的聚乳酸-聚乙醇酸共聚物(PLGA)纳米粒子(NPs)对损伤-狭窄小型猪冠状动脉损伤后平滑肌增殖、基质金属蛋白酶(MMP)-2、基质金属蛋白酶抑制物(TIMP)-2及p27^kip1mRNA表达的影响。方法28头小型猪模型随机数字表法分为4组,每组7只,冠状动脉过大球囊损伤后经Dispatch^TM球囊局部分别灌注生理盐水、5.0mg/ml空白NPs、1.0mg/ml RPM和5.0mg/ml RPM—PLGA NPs。手术第30天复查造影并留取冠脉标本。评价干预前后各组冠脉造影血管狭窄程度,切片常规行苏木精-伊红、Weigert氏间苯二酚复红和苦味酸-天狼星红染色并行形态学比较。免疫组化染色法检测增殖细胞核抗原(PCNA)、MMP-2、TIMP-2,原位杂交法检测p27^kip1 mRNA表达水平。结果共21头小型猪完成实验:生理盐水组、空白PLGANPs组、RPM组及RPM—PLGANPs组分别6、4、5、6头。各组间损伤-狭窄模型造成的即刻损伤程度无统计学意义,RPM—PLGANPs组第30天造影血管狭窄程度明显低于生理盐水和空白NPs组(P〈0.01)和RPM组(P〈0.05)。RPM—PLGANPs组新生内膜面积NIA、内外弹力板围绕面积比值及增生指数显著小于其他三组(均P〈0.05),而最大内膜厚度MIT、内弹力板围绕面积IELA大于其他三组(均P〈0.05)。RPM—PLGANPs组阳性区域平均积分光密度值为0.35±0.06,显著高于空白NPs组(0.12±0.05,P〈0.01)及生理盐水、RPM组(0.16±0.03和0.15±0.03,P〈0.05),MMP-2/TIMP-2比值及PCNA组化染色阳性表达指数及均低于其余三组(均P〈0.05)。结论RPM-PLGA NPs结合Dispatch^TM球囊血管腔内给药抑制损伤后小型猪冠状动脉VSMC增殖和细胞外基质生成而抑制再狭窄发生,是用于治疗血管增殖性疾患有临床前景的手段之一。 Objective To determine whether intramural administration of rapamycin (RPM)- loaded polylactic-polyglycolic acid (PLGA) nanoparticles (NPs) can reduce intimal thickening and affect the mRNA expressions of matrix metalloproteinase (MMP) -2, tissue inhibitor of metalloproteinase (TIMP) - 2 and p27^kip1 in a coronary injury-stenosis model of minipigs. Methods Twenty eight minipigs were randomly separated into four groups: saline group (n =7), blank PLGA NPs group (5.0 mg/ml) (n =7),RPM group ( 1.0 mg/ml ) ( n = 7 ), and RPM-PLGA NPs ( 5. 0 mg/ml ) group ( n = 7 ), respectively. Different treatments were intracoronary locally delivered via a Dispatch^TM catheter for 10 minutes. Serial angiography was performed pre-and post-modeling 30 days and the percent stenosis degree was assessed. Hematoxylin-Eosin (HE) staining, Weigert's resorcin fuchsin staining and picric acid-sirius red staining were used for morphometric analysis. Immunohistochemistry was performed to assess the levels of proliferating cell nuclear antigen ( PCNA), MMP-2, and TIMP-2 at early and late time points, respectively. The expression of p27^kip1 mRNA was detected by in sitn hybridization staining. Results Data from 21 minipigs had been collected at the end of the experiment with 6, 4, 5, and 6 from the former mentioned 4 groups, respectively. For the instant injury index, there was no significant difference among the four groups. The percent stenosis degree of RPM-PLGA NPs group was significantly lower than that of the other three groups respectively ( all P 〈 0.05 ). The neointima area, net external elastic lamina area to external elastic laminal area ratio, and proliferative index of RPM-PLGA NPs group were significantly less than those of the other three groups, with all the P values less than 0. 05. The mean value of integral optical density of p27^kip1 mRNA expression of RPM-PLGA group was 0. 35 ±0.06, higher than that of blank PLGA NPs group (0. 12 ±0.05, P〈 0.01), saline group (0.16 ±0.03, P〈 0.05), and RPM group (0.15±0.03, P〈 0.05 ), respectively. The MMP-2/TIMP-2 ratio and the positive expression index of PCNA in RPM-PLGA group were lower than that of the other groups ( P 〈 0. 05 ). Conclusions Locally delivered rapamyeinloaded PLGA NPs significantly reduces MMP-2/TIMP-2 ratio and PCNA expression, increases p27^kip1 mRNA expression and significantly relieves percent stenosis degree and shows excellent acute procedural results in the minipig interventional coronary artery oversized balloon injury model. The results from minipig model further support that this approach could be a potential clinical procedure for vascular proliferative disease.
出处 《中华医学杂志》 CAS CSCD 北大核心 2016年第1期36-42,共7页 National Medical Journal of China
基金 国家自然科学基金(30240021) 清华-裕元医学科学研究基金(20240000556)
关键词 雷帕霉素 聚乳酸-聚乙醇酸共聚物纳米粒子 小型猪 冠状动脉再狭窄 局部给药 Rapamycin Poly ( lactic-co-glycolic ) acid nanoparticles Minipig model Coronary restenosis Local drug delivery
  • 相关文献

参考文献18

  • 1Claessen BE, Henriques JP, Jaffer FA, et al. Stent thrombosis : a clinical perspective [ J 1. JACC Cardiovasc Interv, 2014, 7 (10) : 1081-1092. DOI:10. 1016/j. jcin. 2014.05. 016.
  • 2Tesfamariam B. Local vascular toxicokinetics of stent-based drug delivery[ J ]. Toxicol Lett, 2007, 168 ( 2 ) : 93-102. DOI: 10. 1016/j. toxlet. 2006.11. 013.
  • 3Habara S, Kadota K, Shimada T, et al. Late Restenosis After Paclitaxel-Coated Balloon Angioplasty Occurs in Patients With Drug-Eluting Stent Restenosis[ J]. J Am Coll Cardiol, 2015, 66 ( 1 ) :14-22. DOI:IO. 1016/j. jacc. 2015.05. 002.
  • 4Kawashima H, Suzuki N, Kyono H, et al. Incidence, predictors and outcomes of immediate decrease in thrombolysis in myocardial infarction flow immediately after paclitaxel-coated balloon angioplasty[ J 1. Int J Cardiol, 2015, 191 : 223-224. DOI: 10. lO16/j, ijcard. 2015.05. 046.
  • 5Ikenaga H, Kurisu S, Ishibashi K, et al. Slow-flow phenomenon after Paclitaxel-coated balloon angioplasty: findings from optical coherence tom0graphy and coronary angioscopy [ J 1. JACC Cardiovasc Interv, 2015, 8 (4) : e59-e62. DOI : 10. 1016/j. jcin. 2014.11. 016.
  • 6Haddadi A, Elamanchili P, Lavasanifar A, et al. Delivery of rapamycin by PLGA nanoparticles enhances its suppressive activity on dendritic cells[J]. J Biomed Mater Res A, 2008, 84-(4) :885- 898. DOI:10. 1002/ibm. a. 31373.
  • 7苗立夫,杨菁,黄超联,宋存先,曾玉杰,陈连凤,朱文玲.雷帕霉素聚乳酸-聚乙醇酸纳米粒子的制备、表征及血管内局部给药效能[J].中国医学科学院学报,2008,30(4):491-497. 被引量:6
  • 8苗立夫,朱文玲.雷帕霉素防治冠状动脉再狭窄的研究进展[J].临床心血管病杂志,2003,19(9):563-565. 被引量:4
  • 9Danhier F, Ansorena E, Silva JM, et al. PLGA-based nanoparticles: an overview of biomedical applications [ J ]. J Control Release, 2012, 161 ( 2 ) : 505-522. DOI: 10. 1016/j. jconrel. 2012.01. 043.
  • 10Acharya S, Sahoo SK. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect [ J ]. Adv Drug Deliv Rev, 2011, 63(3) :170-183. DOI: 10. lO16/j, addr. 2010.10. 008.

二级参考文献31

  • 1曾勇,朱文玲,朱振峰,宋存先,杨菁.纳米粒子携带地塞米松局部腔内注射预防球囊损伤后再狭窄的实验研究[J].中国介入心脏病学杂志,2001,9(3):115-117. 被引量:4
  • 2Abranham R T, Wiederrecht G J. Immunopharmacology of rapamycin. Annu Rev Immunol. 1996,14: 483--510.
  • 3Ruygrok P N, Muller D W, Serruys P W. Rapamycinin cardiovascular medicine. Intern Med J, 2003, 33 : 103-109.
  • 4McMahonLP, ChoiK M, LinT A, et al. The rapamycin-binding domain governs substrate selectivity by mammalian targer of rapamycin. Mol Cell Biol, 2002,22:7428--7438.
  • 5Fingar D C, Salama S, Tsou C, et al. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP/eIF4E. Genes Dev, 2002, 16: 1472--1487.
  • 6Stawowy P, Blaschke F, Kilimnik A, et al. Proprotein convertase PC5 regulation by PDGF-BB involves PI3-Kinase/p70s6-Kinase activation in vascular smooth muscle cells. Hypertension, 2002,39 : 399--404.
  • 7Hashemolhosseini S, Nagamine Y, Morley S, et al.Rapamycin inhibition of the G1 to S transition is mediated by effets on Cyclin D1 mRNA and proterin stability.J Biol Chem, 1998,273: 14424--14429.
  • 8Klugherz B, Llanos G, Lieuallen W, et al. Stent-based delivery of sirolinus for the prevention of restenosis. J Am Coil Cardiol, 2000,35 :58-- 58.
  • 9Lima V C, Rosa W C, Arruda J A, et al. Efficacy and safety of oral sirolimus to treat and prevent in-stent restenosis: Results of a pilot study. Am J Cardiol,2002,90(Suppl 6A) :11H--11H.
  • 10Degertekin M, Serruys P W, Foley D P, Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation long-term (Up to 2 years) clinical,angiographic, and Intravascular ultrasound follow-up.Circulation, 2002,106: 1610--1613.

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部